SAN DIEGO, CA - January 20, 2026 (NEWMEDIAWIRE) - AXIM Biotechnologies, Inc. (“AXIM” or the “Company”) (OTC:AXIM), a diagnostic and biotechnology company advancing clinically validated solutions for ocular and inflammatory diseases, today announced the engagement of 624 Advisors, which is owned and managed by Alan J. Touch, OD, as Chief Medical & Regulatory Affairs Advisor. Dr. Touch is considered a preeminent IVD and CDx SME and global regulatory specialist.

Dr. Touch brings more than three decades of global leadership across diagnostics, medical devices, pharmaceuticals, and digital health. He is the original co-inventor of the first ocular diagnostic technologies acquired by AXIM, the inventor of the world’s first colored contact lens, formerly headed up Clinical Affairs at Bausch & Lomb and was Principal Strategist for Ophthalmology, Medical Devices and Diagnostics at INC Research (Syneos Health). As Chief Science Officer of an ophthalmic CDMO, he led the development of several proprietary dry eye disease (DED) products including the first eye drop based on addressing the Inflammatory Cascade through a novel pathway. He has been a successful health care entrepreneur as well as providing senior leadership roles for major international healthcare organizations. He founded 624 Advisors as a product development, regulatory and quality compliance consultancy. The engagement of 624 Advisors, led by Dr. Touch, provides AXIM with enhanced technical continuity, regulatory depth, and strategic execution capability at a pivotal stage of the Company’s development.

“This strategic engagement is an important addition to the R&D and regulatory team at AXIM,” said Catalina Valencia, President and CEO of AXIM Biotechnologies. “Dr. Touch uniquely combines inventor-level knowledge of our technology with significant senior level experience in FDA regulation, ISO quality systems, clinical development, and manufacturing readiness. His involvement strengthens our regulatory strategy, quality foundation, and clinical execution, while positioning AXIM for efficient global expansion and long-term operational scale. As AXIM advances toward key regulatory and commercial milestones, including upcoming FDA 510(k) submissions, international regulatory expansion, and the establishment of a robust quality and manufacturing infrastructure, Dr. Touch’s advisory role is designed to provide highly qualified support across these areas. AXIM is very pleased to welcome Dr. Touch to our team.”

Dr. Touch's background uniquely aligns with AXIM's current efforts and upcoming goals and milestones:

• Inventor-level understanding of lactoferrin and immunoassay diagnostics
• Deep experience across FDA, EU MDR/IVDR, and global regulatory frameworks
• Proven leadership in regulatory affairs, quality systems, clinical development, and manufacturing scale-up
• Reduced reliance on external consultants
• Accelerated readiness for commercialization and global growth
• Knowledge of the methodology to build a milestone-based product development Vale Proposition

“I am pleased to work with AXIM at this important stage and to continue advancing technology I originally helped develop,” said Dr. Alan J. Touch. “AXIM is building a strong foundation for market-sensitive and aware regulatory excellence and clinical credibility for its products. I look forward to supporting an excellent and cohesive scientific, marketing and operational team as they advance key submissions, strengthen quality systems, and prepare for long-term manufacturing and commercial success.”

About AXIM Biotechnologies, Inc.

AXIM Biotechnologies, Inc. develops and commercializes rapid , point-of-care diagnostic tests focused on ocular and systemic health. Its TearScan® platform enables clinicians to quantify tear biomarkers with laboratory-grade accuracy in office settings, enhancing diagnostic confidence and treatment outcomes. For more information, visit www.aximbiotech.com.

Corporate/Media Contact
+1 858-256-5132
hello@aximbiotech.com

Forward-Looking Statements

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the statements made herein.

View the original release on www.newmediawire.com

This contant was orignally distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is AXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor.